SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that Annals of Oncology, the journal of the European Society of Medical Oncology, has published a pivotal study validating the Prosigna™ Breast Cancer Prognostic Gene Signature Assay for predicting the risk of distant recurrence in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer.
Help employers find you! Check out all the jobs and post your resume.
